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Abstract
 
The recently described ligand–receptor pair, B7h–inducible costimulator (ICOS), is critical for
germinal center formation and antibody responses. In contrast to the induced expression of the
related costimulatory ligands B7.1 and B7.2, B7h is constitutively expressed on naive B cells
and is surprisingly extinguished after antigen engagement and interleukin (IL)-4 cytokine sig-
naling. Although signaling through both B cell receptor (BCR) and IL-4 receptor (R) con-
verge on the extinction of B7h mRNA levels, BCR down-regulation occurs through Ca
 
2
 
 
 
mobilization, whereas IL-4R down-regulation occurs through a distinct Stat6-dependent path-
way. During antigen-specific B cell activation, costimulation through CD40 signaling can re-
verse both BCR- and IL-4R–mediated B7h down-regulation. These data suggest that the
CD40–CD40 ligand signaling pathway regulates B7h expression on activated B cells and may
control whether antigen-activated B cells can express B7h and costimulate cognate antigen–acti-
vated T cells through ICOS.
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Introduction
 
Collaboration between cognate lymphocytes is essential for
generating effective immune responses to T cell–dependent
antigens. In addition to antigen–receptor engagement, both
B and T cells must also receive costimulatory signals to
proliferate, elicit specific downstream effector functions,
and generate memory (1–3). Costimulatory ligand–recep-
tor pairs expressed on B and T cells, respectively, include
the well-known CD40-CD40 ligand (L;
 
* 
 
CD154), and
B7.1 (CD80)-CD28 and B7.2 (CD86)-CD28 ligand re-
ceptors (4, 5), as well as the more recently described B7h
(also known as B7RP-1, GL50, inducible costimulator
[ICOS]L)-ICOS ligand receptor (6–13). Mice deficient in
CD40 (14), CD40L (CD154; references 15 and 16), B7.1
(CD80) and B7.2 (CD86; reference 17), CD28 (18, 19),
and ICOS (20–23) all exhibit impaired germinal center for-
mation and elicit defective humoral responses to antigen.
The CD40–CD40L signaling pathway is critical for B
cell activation and subsequent differentiation including iso-
type switching and affinity maturation (5). Similarly,
B7.1–CD28 and B7.2–CD28 signaling is crucial for the ac-
tivation of naive T cells, particularly for IL-2 production,
clonal expansion, and survival of antigen-specific T cells
(4). However, although both CD28 and ICOS signaling
can costimulate T cell proliferation, ICOS signaling does
not costimulate IL-2 production, but instead appears more
important for the secretion of several cytokines including
IL-4, IL-5, GM-CSF, TNF-
 
 
 
, IFN-
 
 
 
, and IL-10 (6, 9).
Thus, these costimulatory receptor pairs have both over-
lapping and distinct functions in mediating the activation of
antigen-specific B and T cells.
The expression of these three major costimulatory re-
ceptor pairs is highly regulated on B and T cells. B7.1 and
B7.2 are induced on B cells after activation by innate and
adaptive signals, whereas CD28 is constitutively expressed
on naive and activated T cells (4). In contrast, CD40 is
constitutively expressed on naive and activated B cells,
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whereas CD40L is only expressed on activated T cells (5).
Analogous to CD40-CD40L expression, B7h is also consti-
tutively expressed on B cells (7, 9, 10, 12), whereas ICOS
requires T cell activation to induce its expression on naive
T cells (6, 24).
The expression of these costimulatory molecules is not
only highly regulated, but sequential cross talk between co-
stimulatory receptor pairs during cognate interactions regu-
lates the proper activation of antigen-specific B and T cells.
Costimulation of T cells through CD28 helps stabilize
CD40L expression on activated T cells (25, 26) and recip-
rocal costimulation of B cells through CD40 augments the
expression of B7.1 and B7.2 molecules (27). Although
B7.1–CD28 and B7.2–CD28 interactions are important in
initiating immune responses, ICOS is induced on T cells
after activation, which suggests that B7h–ICOS interac-
tions may play a more important role in costimulating acti-
vated T cells. Indeed, costimulation through CD28 appears
important for optimal expression of ICOS (24, 28). How-
ever, although multiple B cell stimulatory signals are able to
induce B7.1 and B7.2 expression, little is known about the
signals that regulate B7h expression on B cells.
Here we report that expression of B7h on activated B
cells is highly regulated by these three critical B cell signal-
ing pathways: B cell receptor (BCR), IL-4R, and CD40
receptor. After BCR engagement of antigen, constitutive
B7h expression on naive B cells is progressively down-reg-
ulated on activated B cells. The hallmark Th2 cytokine
IL-4 can also progressively down-regulate B7h on naive and
activated B cells. Treatment with both antigen and IL-4
greatly enhance the kinetics and extent of B7h down-regu-
lation, which leads to the extinction of cell surface B7h
expression. Although BCR-mediated down-regulation oc-
curs through Ca
 
2
 
  
 
mobilization, IL-4R–mediated down-
regulation of B7h occurs through the Stat6 transcription
factor, indicating that at least two distinct signaling path-
ways converge on the extinction of B7h mRNA and cell
surface expression on B cells. Costimulation of activated B
cells through the CD40 receptor, however, is capable of
restoring the surface expression of B7h after both antigen-
and IL-4–mediated down-regulation. Reversal of B7h
down-regulation appears to be specific to CD40 signaling
and was not observed with bacterial LPS or with a panel of
innate and adaptive cytokines tested. These results suggest
that the CD40–CD40L signaling pathway regulates B7h
expression on activated B cells and may control whether
antigen-activated B cells reexpress B7h and in turn costim-
ulate cognate antigen–activated T cells through the ICOS
receptor expressed on activated T cells.
 
Materials and Methods
 
Antibodies and Flow Cytometry.
 
Before staining, dead cells
were removed by spinning through Histopaque 1119 (Sigma-
Aldrich) and F
 
c
 
R was blocked by incubating cells with anti-F
 
c
 
R
(2.4G2) hybridoma supernatant. Subsequent staining was per-
formed in staining buffer (HBSS, 2% fetal bovine serum, 10 mM
Hepes, and 0.05% NaN
 
3
 
). Levels of cell surface B7h expression
 
were analyzed for all experiments (except that shown in Fig. 2 D)
by staining with a biotinylated anti-B7h hamster mAb (clone
22D7) generated in Golden Syrian hamsters (29) followed
by a second step phycoerythrin-conjugated streptavidin reagent
(streptavidin-PE; BD PharMingen). For the anti-IgM time course
(see Fig. 2 D), B7h staining was performed with anti-B7h mAb
developed using a biotinylated goat anti–hamster antibody (Cal-
tag) and streptavidin-PE. Levels of B7h staining on naive B cells
were comparable between this 3-step method and the 2-step
method that is used in other experiments for the detection of B7h
(unpublished data). Expression of B7.1 and B7.2 was determined
using a biotinylated anti-B7.1 mAb (16-10A1) or a biotinylated
anti-B7.2 mAb (GL1; BD PharMingen). Background staining was
determined using an appropriate isotype-specific hamster mAb as
a control for anti-B7h and anti-B7.1 staining, or an isotype-spe-
cific rat mAb (BD PharMingen) for anti-B7.2 staining. Expression
of I-A
 
d 
 
on Chinese hamster ovary (CHO) cells used in T cell ac-
tivation assays was determined using an anti–mouse I-Ad
 
b/d
 
mAb (25-9-17; BD PharMingen) followed by staining with biotin-
ylated rat anti–mouse IgG2a (R19-15; BD PharMingen), and de-
veloped using streptavidin-PE. Cells were analyzed on a Coulter
EPICS XL and data plotted using the WinMDI (The Scripps In-
stitute Flow Cytometry Core Facility) program.
 
Mice and Immunization.
 
5–8-wk-old C57BL/6 mice were
obtained from The Jackson Laboratory and used within 1 mo of
receipt. Hen egg lysozyme (HEL)-specific IgM and IgD BCR
transgenic mice (IgHEL; MD4 line; provided by J.G. Cyster,
University of California, San Francisco, CA) on a C57BL/6
background were used between the ages of 5 and 8 wk. DO11.10
TCR transgenic mice on either a BALB/c or B10.DR/recombi-
nation activating gene (RAG)1
 
 
 
/
 
  
 
background were used within
6 mo of age. Stat6
 
 
 
/
 
  
 
and littermate control mice were provided
by K.M. Murphy (Washington University, St. Louis, MO). All
animal procedures were performed in accordance with regula-
tions set by the University of California Berkeley Animal Care
and Use Committee.
C57BL/6 mice were immunized intraperitoneally with 100 
 
 
 
g
(4-hydroxy-3-nitrophenyl)acetyl (NP) coupled to chicken-
 
 
 
globulin (NP
 
15
 
-CG) in alum as previously described (30). For
blocking experiments, mice were treated daily with 100 
 
 
 
g
blocking anti-B7h mAb or control hamster IgG (Jackson Immu-
noResearch Laboratories) for the course of the experiment, start-
ing 1 d before immunization. On day 8, frozen splenic sections
from cohorts of B7h-blocked and control mice were stained for
Ig
 
 
 
  
 
cells using alkaline-phosphatase–labeled goat anti–
 
  
 
anti-
body (Southern Biotechnology Associates, Inc.) or with biotiny-
lated peanut agglutinin (Vector Laboratories) and streptavidin-AP
(Boehringer), and developed with NBT/BCIP (Boehringer) ac-
cording to the manufacturer’s instructions.
 
RNase Protection Assay.
 
RNase protection assay was per-
formed as previously described (10). Activated B cells were har-
vested and washed with 1
 
  
 
PBS. Total cellular RNAs were pre-
pared using Tri-Reagent (Molecular Research Center) according
to the manufacturer’s protocol and 10–15 
 
 
 
g of total RNA was
used to perform each RNase protection assay. Probes for B7h and
 
 
 
-actin were used as previously described (10). RNase protection
assay was run simultaneously for the PMA/ionomycin, CD40L,
and anti-IgM stimulated samples. A separate experiment com-
pared IL-4– and anti-CD40–stimulated samples.
 
B Cell Activation.
 
B cells were purified from total splenocyte
preparations as previously described (31). In brief, red blood cells
were lysed with ammonium chloride and T cells were depleted
by staining with anti-Thy1.2 (13H10) hybridoma supernatant and 
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lysed using rabbit complement (CedarLane). Purified B cells
(
 
 
 
90% B220
 
 
 
) were activated in 12-well plates at a density of 10
 
6
 
cells/ml in lymphocyte media (RPMI 1640, 10% fetal bovine se-
rum, 50 
 
 
 
M 2-ME, 100 U penicillin, and 100 
 
 
 
g/ml streptomy-
cin) in the presence of 10 
 
 
 
g/ml affinity-purified goat anti–IgM
F(ab
 
 
 
)
 
2 
 
fragments (Jackson ImmunoResearch Laboratories), 10
 
 
 
g/ml LPS (Sigma-Aldrich), 250 nM PMA, and 1 
 
 
 
M ionomy-
cin or 200 ng/ml HEL (United States Biochemical) for the indi-
cated times. For experiments examining the effects of CD40 sig-
naling, 5 
 
 
 
g/ml purified activating anti-CD40 mAb (clone 3/23;
BD PharMingen) was added with either HEL or anti-IgM F(ab
 
 
 
)
 
2
 
during the initiation of stimulation, or added to cultures 24 h af-
ter activation with HEL. As a control for the possible effects of
using whole anti-CD40 antibody molecules on B cell stimulation,
a control-purified rat mAb to B7.2 was used with either HEL or
anti-IgM F(ab
 
 
 
)
 
2 
 
to activate B cells. No effect of the control anti-
body on B cell activation or B7h expression was observed (un-
published data). For activation using membrane-bound CD40L
(mCD40L), purified S19 membranes of baculovirus-expressed
CD40L was used at a 1:500 dilution (32, 33). To determine the
effects of cytokines on B7h expression after BCR activation, pu-
rified B cells were activated with HEL as described above in the
presence of 5 ng/ml IL-4 (R&D Systems), IL-5 (1:500), 10 ng/
ml IL-1
 
 
 
 (R&D Systems), IL-2 (R&D Systems), 10 ng/ml TNF-
 
 
 
(R&D Systems), IFN-
 
 
 
 (provided by R. Schreiber, Washington
University, St. Louis, MO), or 10 
 
 
 
g/ml LPS (Sigma-Aldrich).
10 
 
 
 
g/ml cyclosporin A (CsA) was added to unstimulated B cell
cultures or to cultures activated with 10 
 
 
 
g/ml anti-IgM F(ab
 
 
 
)
 
2
 
or PMA and ionomycin.
 
T Cell Activation.
 
To assess the function of B7h expressed on
B cell APCs in priming T cell cytokine production, naive
D011.10 TCR transgenic CD4
 
  
 
T cells were isolated from the
lymph nodes of DO11.10 transgenic mice in the B10.DR/
RAG1
 
 
 
/
 
  
 
background by complement lysis with a cocktail
of anti-MHC (28.16.8S and BP107), anti–heat-stable antigen
(J11D), and anti-F
 
c
 
R (2.4G2) mAbs, and naive B cells (96%
B220
 
 
 
) were purified from BALB/c mice as described above with
an additional panning step to remove adherent cells bound to tis-
sue culture plates at 37
 
 
 
C. 5 
 
  
 
10
 
5 
 
purified CD4
 
  
 
T cells were
cultured with 2.5 
 
  
 
10
 
6 
 
purified B cells in the presence of either 5
 
 
 
g/ml blocking anti-B7h mAb (22D7) or control hamster IgG
(Jackson ImmunoResearch Laboratories) and 0.3 
 
 
 
M OVA pep-
tide (provided by K.M. Murphy) for 4 d. Activated T cells were
purified as described above, rested for 24 h, and rechallenged with
irradiated (1,000 rads) BALB/c splenocytes in the absence of
blocking. Supernatants were harvested at the indicated times and
IL-4 production was assayed by ELISA (BD PharMingen).
Naive DO11.10 TCR transgenic T cells were isolated from
the lymph nodes of DO11.10 transgenic mice in the B10.DR/
RAG1
 
 
 
/
 
  
 
background to examine the effects of costimulation on
CD40L expression (
 
 
 
90% CD4
 
 
 
) as described above. For
rechallenge experiments, DO11.10 transgenic T cells from
DO11.10 transgenic mice in the BALB/c background were acti-
vated in bulk splenocyte cultures in the presence of 0.3 
 
 
 
M OVA
peptide. Cells were expanded over 3 d, purified as described
above, and rested overnight before restimulation. Purified T cells
(
 
 
 
92% CD4
 
 
 
) were determined to express ICOS by staining
with anti-ICOS mAb (provided by J.P. Allison, University of
California, Berkeley, CA) and were CD40L
 
  
 
before rechallenge.
Purified T cells, either naive or previously activated, were ac-
tivated using I-A
 
d
 
–expressing CHO cells retrovirally transduced
with green fluorescent protein, B7h, or B7.2 as previously de-
scribed (29). 4 
 
  
 
10
 
5 
 
irradiated (2,000 rads) CHO cells were
 
plated in 24-well dishes and prepulsed with varying OVA pep-
tide concentrations (0–3 
 
 
 
M) for 2 h. For blocking experiments,
anti-B7h, anti-B7.2, or control hamster IgG were added at a fi-
nal concentration of 10 
 
 
 
g/ml. 5 
 
  
 
10
 
5 
 
T cells were added and
CD40L expression was determined after stimulation for 24 h for
naive T cells and 3 h for previously activated T cells by staining
with biotinylated anti-CD40L (MR1; BD PharMingen) devel-
oped with streptavidin-PE and anti-CD4 FITC. The percentage
of CD40L
 
 
 
CD4
 
  
 
cells was determined by two-color flow cy-
tometry.
 
Results
 
B7h Is Required for Germinal Center, but Not B Cell Foci,
Formation.
 
To examine the function of B7h in regulating
immune responses, we generated three independent IgG
mAbs against B7h by immunizing hamsters with CHO
cells expressing B7h. Two of these mAbs were effective in
both blocking a B7h–Ig fusion protein from binding to
ICOS-transfected 293 cells and in blocking B7h-mediated
costimulation of T cell proliferation (unpublished data).
We used one of these mAbs, clone 22D7, to block in vivo
B7h–ICOS interactions and test the requirement for B7h
in responses to T cell–dependent antigens.
Mice immunized with NP coupled to CG (NP
 
15
 
-CG) in
alum were injected with daily doses of anti-B7h mAb. A
control cohort of immunized mice was also injected in
conjunction with nonspecific hamster IgG. Because the
immune response to NP is characterized by a 
 
 
 
-specific re-
sponse (34), formation of 
 
 
 
  
 
B cell foci early in the re-
sponse could be examined. In cryosections of spleen at day
8, formation of 
 
 
 
  
 
foci was qualitatively and quantitatively
similar in both control mice and mice treated with anti-B7h
mAb (Fig. 1). Quantitation of 
 
 
 
  
 
foci/follicle was 1.65 
 
 
 
0.14 for cryosections from control mice and 1.73 
 
  
 
0.23
for cryosections from mice treated with anti-B7h mAb.
Germinal center formation, which occurs later in an im-
mune response, was also examined in the same splenic cry-
osections. In contrast to foci formation, germinal center
formation was markedly impaired in mice treated with
anti-B7h mAb. Quantitation of germinal centers/follicle
was 0.27 
 
  
 
0.03 for cryosections from control mice and
0.03 
 
  
 
0.04 for cryosections from mice treated with anti-
B7h mAb. These results correspond with the inability of
ICOS
 
 
 
/
 
  
 
mice to form germinal centers (20, 21, 23) and
suggest that B7h is the primary in vivo ligand for ICOS. In
addition, these results indicate that although B7h–ICOS in-
teractions are required later in an immune response for ger-
minal center formation, they are not essential earlier during
B cell foci formation.
 
BCR and IL-4R Signaling Down-regulates Constitutive B7h
on Naive B Cells.
 
A generally accepted paradigm in co-
stimulation is that costimulatory molecules are appropri-
ately up-regulated on APCs in response to proinflamma-
tory innate and adaptive signals (4). For example, immature
dendritic cells express low levels of costimulatory mole-
cules. However, after activation, mature dendritic cells up-
regulate the expression of B7.1 and B7.2 and are extremely 
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effective APCs (35). B7h is also up-regulated on dendritic
cells (12) and is highly expressed on splenic CD11c
 
  
 
den-
dritic cells (Fig. 2 A). Similarly, B7.1 and B7.2 are not ex-
pressed on naive B cells, but are up-regulated after activa-
tion by numerous stimuli including engagement of BCR,
IL-4R, CD40 receptor, and the B cell mitogen, LPS (36–
40). B7h expression, however, differs from B7.1 and B7.2
in that it is highly expressed on naive B cells (7, 10, 12). In
bone marrow, B7h is also expressed on IgM
 
 
 
B220
 
  
 
cells
(unpublished data), indicating that it is expressed before
mature B cell entry into the periphery. Thus, in contrast to
B7.1 and B7.2, which are both induced after B cell activa-
tion, B7h is highly expressed on naive B cells in the bone
marrow and periphery.
The ICOS receptor expressed on activated T cells is es-
sential for the generation of Th2 responses. In ICOS
 
 
 
/
 
 
 
mice (20–22) and in vitro cultures in which B7h–ICOS in-
teractions were blocked (28), activated T cells were defi-
cient for IL-4 and IL-10 production. To determine if B7h
expressed on B cells was a functionally important source of
costimulation for T cell cytokines, we used purified B cells
as APCs to activate DO11.10 TCR transgenic T cells in
the presence or absence of our blocking anti-B7h mAb.
After this initial activation, T cells were rechallenged and
IL-4 production was measured. We observed that IL-4
production was impaired when B7h–ICOS interactions
were blocked compared with control hamster IgG–treated
cultures (Fig. 2 B). These results demonstrate that B7h is
not only highly expressed on B cells, but also has a nonre-
dundant costimulatory function during cognate B cell–T
cell interactions for costimulating IL-4 production (41).
The requirement for B7h–ICOS interactions in T cell–
dependent B cell immune responses highlights the impor-
tance of this signaling interaction after the activation of an-
tigen-specific B cells. Surprisingly, in examining the ex-
pression of B7h on activated B cells, we observed that both
BCR engagement and treatment with IL-4 resulted in the
rapid down-regulation of B7h expression (Fig. 2 C). This
down-regulation of B7h did not appear to be a general
consequence of B cell activation, as activation of naive B
cells through CD40 receptor (42) or the B cell mitogen
LPS did not result in the same rapid down-regulation of
surface B7h levels observed with BCR or IL-4R signaling.
In contrast, as has been previously reported (36–40), all of
the activating stimuli examined rapidly induced B7.2 ex-
pression on naive B cells.
BCR engagement resulted in the down-regulation of
B7h that was progressive and sustained (Fig. 2 D). By 72 h,
the majority of B cells activated with anti-IgM antibodies
no longer expressed B7h that was detectable by flow cy-
tometry, and this occurred again in concert with the induc-
tion of B7.2 on activated B cells at all mitogenic con-
centrations of anti-IgM antibodies. At submitogenic
concentrations of anti-IgM antibodies (
 
 
 
1 
 
 
 
g/ml), no
changes in the surface expression of either B7h or B7.2
were detected (unpublished data). IL-4R–mediated signal-
ing also resulted in the down-regulation of B7h that was
progressive and sustained (unpublished data). Thus, B cell
activation through either BCR or IL-4R engagement re-
sulted in the down-regulation of B7h expression.
 
BCR and IL-4R Extinguish B7h mRNA Levels by Two
Distinct Signaling Pathways.
 
These results prompted us to
examine whether BCR- and IL-4R–mediated down-regu-
lation of surface B7h expression resulted from specific
changes in the levels of B7h mRNA. B7h mRNA levels
were examined in different activated populations of B cells
Figure 1. B7h is required for
the formation of germinal cen-
ters, but not extrafollicular foci.
Mice were immunized with the T
cell–dependent antigen, NP-CG
in alum, and were treated with
daily intraperitoneal injections of
100  g of either a blocking anti-
B7h mAb or a hamster IgG con-
trol. Splenic cryosections at day
8 were analyzed by immunohis-
tochemistry to detect    NP-spe-
cific foci and peanut agglutinin 
germinal centers.  200. 
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that had either maintained or down-regulated surface B7h
expression (Fig. 3). Levels of B7h and control 
 
 
 
-actin
mRNAs were assayed simultaneously using an RNase pro-
tection assay. B7h mRNA was readily detected in activated
B cells treated with anti-CD40 mAb or membrane CD40
ligand (mCD40L), cell populations in which surface B7h
expression was also observed by flow cytometry. In con-
trast, B cells activated with PMA and ionomycin or anti-
IgM antibodies had severely reduced levels of B7h mRNA,
and B cells treated with IL-4 also had decreased amounts of
B7h mRNA. These decreases were specific to B7h
mRNA, as 
 
 
 
-actin mRNA was readily detected in all acti-
vated B cell populations. These results indicate that the
down-regulation of surface B7h expression by both BCR
and by IL-4R signaling lead to the extinction of B7h
mRNA levels.
Next, we examined the proximal signaling pathways
downstream of BCR engagement that lead to the extinc-
tion of B7h mRNA levels by activating naive B cells with
the phorbol ester, PMA, and the Ca
 
2
 
  
 
ionophore, ionomy-
cin (Fig. 4 A). Treatment with the combination of PMA
and ionomycin was observed to down-regulate B7h surface
expression, similar to the down-regulation observed with
BCR signaling. In fact, ionomycin treatment alone was as
effective as PMA and ionomycin, whereas treatment with
PMA alone did not affect B7h surface expression. These
data indicate that Ca
 
2
 
  
 
mobilization downstream of BCR
signaling can mediate B7h down-regulation. Consistent
with this observation, treatment with the inhibitor of cal-
cineurin, CsA, blocked the down-regulation of B7h by
both PMA and ionomycin treatment, and by anti-IgM an-
tibodies (Fig. 4 B). In contrast, CsA treatment did not
block IL-4–mediated B7h down-regulation. These data
suggest that although Ca
 
2 –dependent signaling is neces-
sary for BCR-mediated down-regulation of B7h, IL-4–
mediated down-regulation occurs through a different sig-
Figure 2. Constitutive B7h expression on naive B cells is down-regulated after BCR signaling and by the cytokine, IL-4. (A) B7h is constitutively ex-
pressed on naive B cells and mature splenic dendritic cells. Naive splenic B cells, T cells, and CD11c  splenic dendritic cells were stained for B7h ex-
pression (solid line) compared with staining with an isotype-matched control antibody (shaded histogram). (B) B7h expressed on B cells costimulates IL-4
production by T cells. Purified B cells were used as APCs to activate DO11.10 T cells in the presence of OVA peptide in cultures containing either a
blocking anti-B7h mAb or control hamster IgG for 4 d. T cells were repurified and IL-4 production was assayed 24 and 72 h after rechallenge with
splenic APCs presenting OVA peptide in the absence of blocking. (C) Rapid down-regulation of B7h is induced by BCR and IL-4R signaling. Naive B
cells, or B cells activated for 24 h with anti-IgM F(ab )2, LPS, anti-CD40 mAb, or with IL-4 were stained for B7h or B7.2 expression (solid line) com-
pared with staining with an isotype-matched control antibody (shaded histogram). (D) B7h down-regulation induced by BCR signaling is progressive
and occurs in concert with B7.2 up-regulation. Purified B cells, activated with anti-IgM F(ab )2, were harvested at the indicated times and stained for
B7h and B7.2 expression. Data shown in A and C are representative of at least three independent experiments.
Figure 3. BCR and IL-4 sig-
naling induces the extinction of
B7h mRNA in activated B cells.
Total cellular RNA were pre-
pared from B cells activated with
PMA and ionomycin for 24 h,
anti-IgM F(ab )2 or membrane
CD40L for 72 h, or IL-4 or
anti-CD40 mAb for 48 h.
The mRNA levels of B7h and
 -actin were determined by
RNase protection assay and sam-
ple lanes from autoradiographs
exposed for the same amount of
time are boxed. Cell surface B7h expression as determined by flow cy-
tometry is indicated under each activation condition.102 B7h Regulation on B Cells by BCR, IL-4R, and CD40 Signaling
naling mechanism that also converges on the extinction of
B7h mRNA levels.
IL-4R signaling is mediated by several downstream
events including the activation of the transcription factor,
Stat6 (43). In Stat6 /  B cells (44), IL-4–mediated down-
regulation of B7h was impaired (Fig. 4 C). In contrast,
BCR-mediated down-regulation was not affected in
Stat6 /  B cells. These results indicate that B7h down-reg-
ulation through BCR signaling and the cytokine IL-4 oc-
cur through distinct signaling mechanisms involving Ca2 
mobilization and the activation of Stat6, respectively.
CD40 Signaling Reverses Down-regulation of B7h on Acti-
vated B Cells. The requirement for B7h late in the im-
mune response in germinal center formation suggested that
for antigen-activated B cells to express sufficient B7h to en-
gage ICOS on activated T cells, additional signaling events
might be required to reverse antigen-mediated down-regu-
lation of B7h. To explore what signaling pathways could
lead to the up-regulation of B7h on antigen-activated B
cells, we used IgHEL transgenic B cells, which express
BCR that recognize the antigen, HEL (45). Transgenic B
cells activated with soluble HEL antigen were observed to
down-regulate B7h and induce B7.2 with similar kinetics
to those seen with BCR stimulation by anti-IgM antibod-
ies (Fig. 5 A).
An important signaling pathway in generating T cell–
dependent B cell immune responses is the costimulation of
B cells through CD40 (3, 46–48). To determine whether sig-
nals received through CD40 were capable of affecting anti-
gen-mediated B7h down-regulation, we simultaneously
treated HEL-activated B cells with an activating anti-CD40
mAb (Fig. 5 B). B cells treated with HEL and anti-CD40
mAb showed similar B7h down-regulation at 24 h com-
pared with B cells activated with HEL alone. However, by
48 h B7h expression was restored to levels observed on na-
ive B cells in cultures activated with HEL and anti-CD40
mAb. Treatment with membranes expressing CD40L (32),
which has previously been shown to activate B cell prolif-
eration and facilitate isotype switching (33), was also effec-
tive in rescuing antigen-mediated B7h down-regulation.
The restoration of B7h expression was specific to CD40
signaling. Treatment with an isotype- and species-matched
anti-B7.2 mAb did not alter antigen-mediated B7h down-
regulation (unpublished data). CD40 signaling was also ef-
fective in reversing ongoing antigen-mediated B7h down-
regulation. The addition of activating anti-CD40 mAb
24 h after HEL antigen activation could also reverse B7h
down-regulation on antigen-activated B cells.
To examine whether costimulation through CD40 was
also capable of reversing IL-4–mediated B7h down-regula-
tion, IL-4–activated B cells were also stimulated with an
anti-CD40 mAb (Fig. 5 C). CD40 signaling was also able
to reverse IL-4–mediated down-regulation of B7h within
48 h. Thus, the costimulation of B cells through CD40 sig-
naling was capable of restoring B7h expression on either
antigen- or IL-4–activated B cells.
Figure 4. BCR-mediated B7h down-regulation
occurs through Ca2  signaling, whereas IL-4–mediated
down-regulation occurs through a distinct Stat6-depen-
dent signaling pathway. (A) B7h down-regulation in-
duced by BCR signaling is Ca2  dependent. Purified B
cells were treated for 24h with PMA alone, ionomycin
alone, or a combination of both and stained for B7h
expression. (B) B7h down-regulation by BCR signal-
ing is CsA sensitive. Purified B cells were activated
with PMA and ionomycin, anti-IgM F(ab )2, IL-4, or
untreated either in the presence (solid lines) or absence
(solid filled) of CsA. After 24 h of stimulation, cells
were stained for B7h expression compared with con-
trol staining (shaded histogram). (C) IL-4–mediated
B7h down-regulation is Stat-6 dependent. Purified B
cells from Stat6 /  and wild-type control mice were
either untreated or activated with IL-4, anti-IgM
F(ab )2 and IL-4, or PMA and ionomycin. Cells were
stained for B7h expression after 24 h of culture.103 Liang et al.
IL-4 treatment significantly enhanced the antigen-
induced down-regulation of B7h on activated B cells (Fig.
5 D). This result may have physiological significance given
the in vivo importance of B7h–ICOS signaling in regulat-
ing IL-4 production and Th2 responses. After the stimula-
tion of B cells with both HEL antigen and IL-4, B7h was
down-regulated more rapidly and completely in compari-
son to stimulation with either antigen or IL-4 alone. Again,
CD40 signaling was able to restore B7h expression after ac-
tivation with both HEL antigen and IL-4.
Specificity of CD40 Rescue of B7h Expression. B7h ex-
pression in a variety of cell types is regulated by inflamma-
tory signals. Fibroblasts (10) and bone marrow–derived
macrophages treated with TNF-  (49) induce B7h expres-
sion and mice injected with LPS up-regulate B7h in a vari-
ety of peripheral organs including testes and kidney (10).
These results suggested that in addition to T cell–specific
CD40–CD40L interactions, inflammatory cytokines might
also be important for regulating B7h induction on B cells.
We tested the ability of a variety of inflammatory media-
tors, including bacterial LPS and the inflammatory cyto-
kines TNF- , IL-1, and IL-12 to up-regulate B7h on HEL-
activated transgenic B cells (Fig. 6 A). In contrast to CD40
signaling, treatment with these stimuli was unable to rescue
Figure 5. CD40 signaling rescues BCR-mediated B7h down-regulation. (A) Soluble HEL induces B7h down-regulation on naive transgenic B cells.
Purified B cells from IgHEL transgenic or nontransgenic littermates were activated with HEL or PMA and ionomycin, or left untreated, and stained for
B7h and B7.2 expression (solid lines) compared with staining by an isotype-matched control antibody (shaded histogram) after 48 h of stimulation. Data
are representative of five similar experiments. (B) CD40 signaling rescues HEL-induced B7h down-regulation. B cells from transgenic or nontransgenic
mice were activated with HEL and costimulated through CD40 using an activating anti-CD40 mAb or mCD40L. CD40 stimulation was provided either
simultaneously with HEL 0 or 24 h after HEL activation. At the indicated times, cells were stained for B7h expression (solid line) compared with staining
with an isotype-matched control antibody (shaded histogram). The level of B7h expression on unstimulated B cells is indicated by a dashed line. Data are
representative of two similar experiments. (C) Costimulation through CD40 rescues IL-4–mediated B7h down-regulation. Purified B cells were un-
treated or stimulated with IL-4 or IL-4 and anti-CD40 mAb. After 48 h of activation, cells were stained for B7h (solid lines) compared with control stain-
ing (shaded histogram). (D) IL-4 signaling enhances HEL-mediated B7h down-regulation and costimulation through CD40 rescues B7h down-regula-
tion by the combination of antigen and IL-4. Purified B cells from IgHEL transgenic and nontransgenic animals were activated with soluble HEL in the
presence or absence of IL-4 and costimulation with anti-CD40 mAb. After 48 h of activation, cells were stained for B7h (solid lines) compared to control
staining (shaded histogram).104 B7h Regulation on B Cells by BCR, IL-4R, and CD40 Signaling
B7h expression on antigen-activated B cells. Thus, al-
though inflammation, especially TNF-  treatment, is im-
portant for the induction of B7h in a variety of monocytic
lineage cells, TNF-  signaling does not appear to regulate
B7h expression on B cells.
The specificity of CD40 signaling suggested that T cell
interactions were critical for the reexpression of B7h on B
cells. In addition to CD40L expression, the production of a
variety of cytokines by Th cells is also important for B cell
activation. We tested a panel of T cell cytokines including
IL-2, IL-4, IL-5, IL-13, and IFN-  for their ability to res-
cue B7h expression (Fig. 6 A). Again, the rescue of B7h
expression on B cells appeared to be specific to CD40 sig-
naling. Thus, CD40 signaling appeared to be unique
among the cytokine and signaling pathways we examined
in its ability to up-regulate B7h expression.
We also examined whether the same stimuli could re-
verse B7h down-regulation induced through BCR cross-
linking by anti-IgM antibodies (Fig. 6 B). Again, neither
the cytokines tested nor LPS restored B7h expression on
anti-IgM–treated B cells (unpublished data). Intriguingly,
CD40 signaling was also not effective in restoring B7h ex-
pression on B cells in which BCR was highly cross-linked
by anti-IgM treatment. These data suggest that the ability
of B7h to be reexpressed may also depend on the type of
antigen recognized by the B cell.
Stabilization of CD40L Expression on Activated T Cells by
B7h and B7.2. The CD40–CD40L signaling pathway
plays an important regulatory role for B7h induction on
antigen-activated B cells. Similarly, transient CD40L in-
duction on activated T cells is also potentiated by other co-
stimulatory pathways. Previous studies have demonstrated
that costimulation by B7.1 and B7.2 through CD28 is crit-
ical in stabilizing CD40L expression on activated T cells
(25, 26). A more recent study demonstrated that anti-ICOS
antibodies enhanced the ability of anti-CD3 antibodies to
up-regulate CD40L expression on bead-activated CD4  T
cells (21). Therefore, we directly compared the ability of
B7.1–CD28, B7.2–CD28, and B7h–ICOS signaling path-
ways in regulating CD40L expression on T cells.
We compared the ability of B7h and B7.2 to costimulate
the induction of CD40L expression on either naive or re-
challenged transgenic DO11.10 T cells using I-Ad CHO
cell lines expressing either B7h or B7.2 (Fig. 7 A). The per-
centage of T cells expressing CD40L was determined by
flow cytometry over a broad range of OVA peptide con-
centrations that were effective in costimulating the prolifer-
ation of DO11.10 T cells (Fig. 7 B). For naive T cells, B7.2
was more effective than B7h in inducing CD40L expres-
sion after 24 h of contact with CHO cells (Fig. 7 C), and
this could specifically be blocked using an anti-B7.2 mAb.
Activation with B7h-CHO-IAd cells was less effective at
inducing CD40L expression, however, this effect could still
be inhibited by blocking B7h with an anti-B7h mAb. To
test whether the differences in induction of CD40L by
B7.2 compared with B7h-expressing CHO cells were due
to ICOS expression by the T cells, we preactivated T cells
to induce ICOS expression. CD40L expression was mea-
sured 3 h after rechallenge with the different CHO sub-
lines. Again, B7.2 was more effective than B7h in stabi-
lizing CD40L expression. These studies indicate that
individually, B7.2 is more effective than B7h in stabilizing
CD40L expression on T cells.
Discussion
Costimulatory receptors convey important information
about the pathogenic context in which antigens are recog-
nized by B and T cells. The appropriate induction of co-
Figure 6. Reversal of antigen-induced B7h down-regulation is specific
to CD40 signaling. (A) Cytokines and LPS do not prevent antigen-
induced B7h down-regulation. Purified B cells were activated with solu-
ble HEL antigen and the indicated treatments. After 48 h of stimulation,
cells were stained for B7h expression. Relative B7h expression was deter-
mined as the ratio of mean B7h fluorescence intensity on experimental to
unstimulated B cells. (B) CD40 signaling does not prevent B7h down-reg-
ulation by anti-IgM cross-linking. B cells from transgenic and nontrans-
genic mice were activated with anti-IgM F(ab )2 in the presence or absence
of anti-CD40 mAb. After 48 h, cells were stained for B7h expression.105 Liang et al.
stimulatory molecules by specific proinflammatory and
adaptive signals is a well-established paradigm by which the
transmission of costimulatory signals is controlled. The sig-
nals responsible for regulating the expression of the costim-
ulatory ligands B7.1 and B7.2, as well as CD40L, have been
well studied. Our results indicate that the expression of the
B7h–ICOS costimulatory pair is also highly regulated not
only at the level of ICOS receptor induction on activated
T cells, but also at the level of B7h ligand expression on ac-
tivated B cells.
Although B7h is present on naive B cells, B7h expression
is regulated by the interplay between three important B cell
signaling pathways after activation: BCR, IL-4R, and
CD40 receptor. Engagement of antigen by naive B cells
leads to the progressive and sustained down-regulation of
B7h. This BCR-mediated B7h down-regulation is ob-
served with both IgHEL transgenic B cells treated with sol-
uble HEL antigen and with wild-type B cells treated with
cross-linking anti-IgM antibodies. The down-regulation of
B7h expression by BCR signaling occurs through Ca2 
mobilization and is CsA sensitive.
In addition to BCR signals, signaling by the Th2 cyto-
kine IL-4 is also important for B cell activation and differ-
entiation. Similar to BCR signaling, IL-4 signaling also
down-regulates B7h expression. The combination of both
BCR and IL-4R signaling results in a more rapid and com-
plete extinction of B7h surface expression on activated B
cells. Given the in vivo regulation of Th2 responses and IL-4
production by B7h–ICOS signaling, this observation is
likely to be physiologically significant. However, although
BCR-mediated B7h down-regulation occurs through a
Ca2 –dependent mechanism, IL-4–mediated down-regu-
lation occurs through a Stat6-dependent signaling pathway,
which is not inhibited by CsA treatment.
Therefore, it appears that the convergence of the
two signaling pathways, Ca2  mobilization downstream of
BCR engagement and Stat6-dependent signaling down-
stream of IL-4R engagement, results in the sustained ex-
tinction of cell surface B7h expression. Importantly, the
loss of surface B7h expression is accompanied by the loss of
B7h mRNA expression in both BCR- and IL-4–stimu-
lated B cells. This suggests that the down-regulation of B7h
may occur by signals that repress B7h transcription. Recent
reports have shown that Ca2  signaling in T cells is not
only capable of activating the expression of a wide variety
of genes, but can also repress the expression of a number of
genes including cell surface molecules (50). In addition,
Stat6-dependent events have also been shown to activate
and repress a large number of different genes (51). Further-
more, the IL-4 effect on B7h expression on B cells can also
be observed in other cell types. CD34  bone marrow–
derived monocytes induce B7h expression after TNF- 
treatment, which is inhibited by IL-4 treatment (49). Addi-
tional studies, however, will be necessary to determine pre-
cisely what signaling molecules are directly responsible for
B7h down-regulation.
Studies of ICOS /  mice have revealed that in the ab-
sence of B7h–ICOS signaling, T cell proliferation and
cytokine production are defective, especially the Th2 cy-
tokines IL-4 and IL-13, and B cell responses to T cell–
dependent antigens are impaired (20–23). The defects in
ICOS /  mice are similar to those observed in other co-
stimulatory molecule–deficient mice, indicating that B7h–
ICOS interactions are playing an important role for the
Figure 7. Costimulation by B7.2 is more effective than B7h in stabilizing CD40L expression on activated T cells. (A) Expression of B7h, B7.2, and I-Ad
(filled histograms) on CHO cell lines compared with control staining (shaded histograms). (B) Representative expression of CD40L on naive compared
with activated T cells. (C) Induction of CD40L expression after the activation of naive or rechallenged DO11.10 transgenic T cells by B7h, B7.2, or con-
trol CHO cells prepulsed with different concentrations of OVA peptide in the presence or absence of blocking anti-B7h or anti-B7.2 mAb. CD40L ex-
pression was measured and plotted as the percentage of CD4  T cells expressing CD40L. Error bars indicate the standard deviation of duplicate samples.
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generation of in vivo immune responses. Given this impor-
tant in vivo function, the reestablishment of high levels of
B7h expression on activated B cells is likely to be important
for the appropriate progression of T cell–dependent B cell
responses. Consistent with this notion, we observed that
the costimulation of activated B cells through CD40 recep-
tor was capable of restoring the surface expression of B7h
after both antigen- and IL-4–mediated down-regulation.
The reversal of B7h down-regulation was specific to CD40
signaling and was not observed with bacterial LPS or with a
panel of innate and adaptive cytokines tested. These results
indicate that the CD40–CD40L signaling pathway regu-
lates B7h expression on activated B cells. Furthermore, be-
cause B7h induction is dependent on CD40–CD40L inter-
actions, our results suggest that the reestablishment of B7h
expression may serve as an important checkpoint to ensure
proper B cell–T cell conjugate formation.
Previous studies (21) indicate that B7h–ICOS signaling
stabilizes CD40L expression on activated T cells. However,
our results, comparing the relative ability of B7.2 and B7h
to costimulate CD40L expression on activated T cells, sug-
gest that B7h is less effective than B7.2 in the induction/
stabilization of CD40L expression. This greater effective-
ness of B7.2 in costimulating CD40L expression on T cells
is consistent with the established role of B7.1–CD28 and
B7.2–CD28 interactions in the initial activation of naive T
cells by mature dendritic cells (35). From this perspective,
we note that CD11c  splenic dendritic cells express lower
levels of B7h than are observed on resting B cells. After ac-
tivation, only the expression of B7.1 and B7.2, and not
B7h, is highly induced (unpublished data). These observa-
tions are consistent with the notion that in initial interac-
tions of T cells with dendritic T cells, costimulation by
B7.1 and B7.2 play a more important role than costimula-
tion by B7h. Additional studies, however, will be required
to establish the precise sequence of cross-regulatory events
involving B7.1–CD28, B7.2–CD28, CD40–CD40L, and
B7h–ICOS costimulatory interactions in vivo.
The ability of BCR and IL-4R signaling to down-regu-
late B7h expression implies that similar to B7.1 and B7.2,
B7h also likely needs to be up-regulated for activated B
cells to maximize costimulatory ICOS signaling into anti-
gen-activated T cells. We suggest that there may be several
reasons why multiple B7 molecules are up-regulated during
the immune response. First, the ability of B7h to be up-
regulated on antigen-activated B cells appears to be more
restricted than that of B7.1 and B7.2. Although multiple
signals including CD40, BCR, and LPS are all capable of
inducing B7.1 and B7.2 expression on activated B cells,
only CD40 signaling was identified in our studies as being
capable of up-regulating B7h. These results suggest that in
the absence of appropriate CD40 signaling in B cells, ICOS
signaling may be suboptimal. Therefore, B7h induction ap-
pears to be more critically dependent on the establishment
of proper cognate interactions between activated T and B
cells than B7.1 or B7.2 induction.
Second, different B7 molecules may play an important
role at different phases during the immune response. Re-
sults from in vivo B7h blocking studies are consistent with
a role for B7h–ICOS interactions in regulating later im-
mune events after exposure to T cell–dependent antigens.
Mice treated with the blocking anti-B7h antibody are still
capable of forming antigen-specific extrafollicular foci, an
event observed early during the immune response. How-
ever, later events such as germinal center formation are se-
verely impaired. This observation is similar to data from
ICOS /  mice. Furthermore, the phenotype of ICOS / 
mice is similar to that observed in CD28 /  mice (19). Be-
cause of the role B7h-ICOS may play in later immune
events, it is possible that B7h–ICOS interactions may play a
more important role for germinal center formation as intact
B7.1–CD28 and B7.2–CD28 signaling in ICOS-deficient
mice is functionally unable to compensate for deficient sig-
naling through B7h-ICOS. Data indicating that the co-
stimulation of T cells through CD28 is necessary for opti-
mal ICOS induction (24, 28) may further suggest that some
of the defects in later immune events observed in CD28 / 
mice may be due to the failure to induce ICOS. Although
B7h–ICOS interactions may not be critical for initiating
immune responses, this costimulatory pathway likely plays
an important role later in the immune response for estab-
lishing correct cognate interactions between activated B
and T cells, and subsequent differentiation.
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